You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
The second messenger cyclic guanosine 3′,5′-monophosphate (cGMP) controls many cellular functions ranging from growth to contractility. Generated from guanylyl cyclases in response to natriuretic peptides or nitric oxide, cGMP transduces its effects through a number of cGMP effectors, including cGMP-regulated phosphodiesterases and protein kinases. Drugs that modulate cGMP levels are emerging as promising therapies, particularly for cardiovascular disorders. This report summarizes new data on the molecular mechanisms, (patho)physiological relevance, and therapeutic potential of the cGMP signaling system that were presented at the 3rd cGMP meeting held in June 2007 in Dresden, Germany.
